###begin article-title 0
Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
###end article-title 0
###begin p 1
Conceived and designed the experiments: JKG JZ JS HS HY MP LG WWL WLL MG JDM AFG. Performed the experiments: JKG JZ JS HS WZ HY MP WWL. Analyzed the data: JKG JZ YX JS LG WWL MG AFG. Contributed reagents/materials/analysis tools: WLL MG JDM. Wrote the paper: JKG JZ YX JS WZ HY WWL WLL MG JDM AFG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 263 267 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. Mutations of EGFR (mEGFR) and copy number gains (CNGs) of EGFR (gEGFR) and HER2 (gHER2) have been reported to predict for TKI response. Mutations in KRAS (mKRAS) are associated with primary resistance to TKIs.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 135 139 135 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 147 156 147 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3 HER4</italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 644 648 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 875 879 875 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 964 968 964 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 973 977 973 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines. Genes studied were EGFR, HER2, HER3 HER4, KRAS, BRAF and PIK3CA. Mutations were detected by sequencing, while CNGs were determined by quantitative PCR (qPCR), fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay. For any of the seven genes tested, mutations (39/77, 50.6%), copy number gains (50/77, 64.9%) or either (65/77, 84.4%) were frequent in NSCLC lines. Mutations of EGFR (13%) and KRAS (24.7%) were frequent, while they were less frequent for the other genes. The three techniques for determining CNG were well correlated, and qPCR data were used for further analyses. CNGs were relatively frequent for EGFR and KRAS in adenocarcinomas. While mutations were largely mutually exclusive, CNGs were not. EGFR and KRAS mutant lines frequently demonstrated mutant allele specific imbalance i.e. the mutant form was usually in great excess compared to the wild type form. On a molar basis, sensitivity to gefitinib and erlotinib were highly correlated. Multivariate analyses led to the following results:
###end p 5
###begin p 6
###xml 5 9 5 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance.
###end p 6
###begin p 7
###xml 5 9 5 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
 2. mKRAS was associated with increased in vitro resistance to gefitinib.
###end p 7
###begin title 8
Conclusions/Significance
###end title 8
###begin p 9
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
Our in vitro studies confirm and extend clinical observations and demonstrate the relative importance of both EGFR mutations and CNGs and HER2 CNGs in the sensitivity to TKIs.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 64 67 64 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Sun1">[1]</xref>
###xml 243 246 243 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Jemal1">[2]</xref>
Lung cancer is the leading cause of all cancer deaths worldwide [1]. Despite the recent advances in diagnosis and multimodality therapies for lung cancers, the prognosis still remains poor with 5-year survival rates of only 16% for all stages [2].
###end p 11
###begin p 12
###xml 246 249 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu1">[3]</xref>
###xml 285 289 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 393 396 393 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Rowinsky1">[4]</xref>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 523 526 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Hirsch1">[5]</xref>
###xml 528 532 528 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 592 595 592 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Nicholson1">[6]</xref>
###xml 788 804 788 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR(HER1/ERBB1)</italic>
###xml 806 824 806 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2 (ERBB2/EGFR2)</italic>
###xml 826 844 826 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3 (ERBB3/EGFR3)</italic>
###xml 849 867 849 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4 (ERBB4/EGFR4)</italic>
Lung cancer is characterized by the accumulation of multiple genetic and epigenetic alterations including somatic mutations and gene copy number gains or both which results in the activation of oncogenes or inactivation of tumor suppressor genes [3]. Epidermal growth factor receptor (EGFR) deregulation has been observed in multiple tumor types including non-small cell lung cancers (NSCLCs) [4]. Hirsch et. al. identified frequent EGFR protein over expression (62%) in NSCLCs of squamous cell and adenocarcinoma subtypes [5]. EGFR over expression is often associated with adverse prognosis [6]. The receptor tyrosine kinase (RTK) super-family of cell surface receptors serves as mediators of cell signaling by extra-cellular growth factors. Members of the ERBB family of RTKs including EGFR(HER1/ERBB1), HER2 (ERBB2/EGFR2), HER3 (ERBB3/EGFR3) and HER4 (ERBB4/EGFR4) have received much attention given their strong association with malignant proliferation.
###end p 12
###begin p 13
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 123 126 123 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Sharma1">[7]</xref>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 340 343 328 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu1">[3]</xref>
###xml 345 348 333 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Eberhard1">[8]</xref>
###xml 350 354 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 500 504 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 569 573 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 679 682 667 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Gazdar1">[9]</xref>
###xml 747 751 735 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 776 780 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 799 803 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu2">[10]</xref>
###xml 805 809 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 828 832 792 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Soung1">[11]</xref>
###xml 834 838 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 857 861 809 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Naoki1">[12]</xref>
###xml 867 873 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 892 896 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Samuels1">[13]</xref>
###xml 898 902 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
The RAS/MAPK and PI3K/AKT pathways are major signaling networks linking EGFR activation to cell proliferation and survival [7]. As discussed below, EGFR signaling pathway genes have been reported to be mutated in NSCLC. Depending on the geographical location, EGFR and KRAS mutations have been identified in approximately10% -30% of NSCLCs [3], [8]. EGFR mutations are independently associated with adenocarcinoma histology, East Asian ethnicity, never smoking status and female gender. Mutations of KRAS also target adenocarcinoma histology, but otherwise differ from EGFR mutations because they are relatively rare in East Asians and occur more frequently in males and smokers [9]. Less commonly, somatic mutations have also been found in other EGFR pathway genes including HER2 (approximately2%) [10], HER4 (approximately2%) [11], BRAF (approximately2%) [12], and PIK3CA (approximately4%) [13], [14].
###end p 13
###begin p 14
###xml 142 146 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Lockwood1">[15]</xref>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Gene copy number gains (CNGs) due to focal amplification or chromosomal polysomy, is one of the other major mechanisms of oncogene activation [15]. Lockwood et al. identified multiple components of the EGFR pathway signaling were frequently amplified and over-expressed in NSCLC. Interestingly, they also found that EGFR pathway gene amplification was more frequent in the adenocarcinoma subtype of NSCLC.
###end p 14
###begin p 15
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 384 388 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 456 459 456 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Sharma1">[7]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Pawson1">[16]</xref>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Chen1">[17]</xref>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Fukuoka1">[18]</xref>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Kris1">[19]</xref>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shepherd1">[20]</xref>
###xml 781 785 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 908 912 908 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Lynch1">[21]</xref>
###xml 914 918 914 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Paez1">[22]</xref>
###xml 920 924 920 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Pao1">[23]</xref>
###xml 1002 1006 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1090 1094 1090 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Uramoto1">[24]</xref>
###xml 1155 1159 1155 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1242 1246 1242 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1395 1399 1395 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shepherd2">[25]</xref>
###xml 1435 1439 1435 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1452 1456 1452 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 1456 1460 1456 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Cappuzzo1">[26]</xref>
###xml 1465 1470 1465 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR3</italic>
###xml 1470 1474 1470 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Cappuzzo2">[27]</xref>
###xml 1604 1608 1604 1608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1645 1649 1645 1649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Pao2">[28]</xref>
###xml 899 907 <span type="species:ncbi:9606">patients</span>
###xml 963 971 <span type="species:ncbi:9606">patients</span>
Because of the frequent deregulation of EGFR pathway genes in NSCLC, EGFR became one of the first rationally selected molecules for targeted therapy. While initial targeted approaches utilized monoclonal antibodies which block the ligand-receptor interaction, newer approaches have utilized small molecule reversible tyrosine kinase inhibitors (TKIs). The tyrosine kinase activity of EGFR is required for the biochemical responses induced by this receptor [7], [16], [17]. Two TKIs, gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech) have been widely used in the treatment of advanced or recurrent NSCLC. Responses were noted in subsets, notably East Asian ethnicity, female gender, never smoking status and adenocarcinoma histology [18], [19], [20]. Subsequently, EGFR mutations were identified in the tyrosine kinase domain, and predicted for response to TKI in the same subset of patients [21], [22], [23]. According to a meta-analysis of 1170 patients, more than 70% of NSCLCs with EGFR mutations responded to TKIs, whereas 10% of tumors without EGFR mutation responded [24]. However, further studies indicated that factors other than EGFR mutations may play a role in determining response and survival after TKI therapy. EGFR gene copy number gain was associated with significantly improved TKI sensitivity and survival in a large unselected study with appropriate controls [25]. In addition, other members of the EGFR family i.e. HER2[26] and EGFR3[27] may be important factors involved in TKI sensitivity. A further complexity is the clinical observation that somatic mutations of KRAS confer intrinsic resistance to TKIs [28].
###end p 15
###begin p 16
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3</italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
To further understand the relationship between TKI sensitivity and deregulation of EGFR pathway genes, we examined the mutation and copy number status of seven of these genes (EGFR, HER2, HER3, HER4, KRAS, BRAF, and PIK3CA) in a large panel of lung cancer cell lines and correlated the data with in vitro sensitivity to TKIs.
###end p 16
###begin title 17
Materials and Methods
###end title 17
###begin title 18
Tumor Cell Lines
###end title 18
###begin p 19
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Galanis1">[29]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Phelps1">[30]</xref>
###xml 552 556 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Paez1">[22]</xref>
###xml 988 992 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Ramirez1">[31]</xref>
###xml 835 840 <span type="species:ncbi:9606">human</span>
We studied a total of 112 cell lines consisting of 77 NSCLC and 32 small cell lung cancer (SCLC) and three lines from small cell cancers at extrapulmonary sites (extrapulmonary small cell cancers, ExPuSC) [29]. All except three of these cell lines were established by the authors [30] at one of two locations. Cell lines initiated at the NCI have the prefix NCI-H while lines established at UT Southwestern have the prefix HCC. NCI-H3255 was obtained from Dr. Bruce Johnson (Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA) [22]. PC-9 (originally from the Tokyo Medical University, Tokyo, Japan) was obtained from Dr. Bert Vogelstein (Johns Hopkins University School of Medicine, Baltimore, MD). Calu-3 was purchased from American Type Culture Center (Manassas, VA). We also investigated eight immortalized human bronchial epithelial cell lines (HBECs, HBEC1KT, HBEC3KT, HBEC4KT, HBEC5KT, HBEC17KT, HBEC30KT, HBEC31KT and HBEC34KT), which were initiated by us [31].
###end p 19
###begin p 20
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Ramirez1">[31]</xref>
###xml 466 467 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 87 93 <span type="species:ncbi:9913">bovine</span>
###xml 302 308 <span type="species:ncbi:9913">bovine</span>
Most of the tumor cell lines were maintained in RPMI1640 supplemented with 5-10% fetal bovine serum (FBS). A few cell lines were grown in ACL4 (for NSCLC lines) and HITES (for SCLC lines) supplemented with 5% FBS. All HBEC cell lines were maintained in Keratinocyte-SFM (Invitrogen, Carlsbad, CA) with bovine pituitary extract (BPE) and recombinant epidermal growth factor (EGF) [31]. All cell lines were incubated at 37degreesC in a humidified atmosphere with 5% CO2.
###end p 20
###begin p 21
The genetic fingerprint of each cell line was obtained (Powerplex 1.2 system, Promega, Madison, WI) and each cell line had a unique genetic profile which was identical to the profiles obtained from the American Type Culture Collection.
###end p 21
###begin title 22
DNA and RNA extraction
###end title 22
###begin p 23
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu3">[32]</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
Genomic DNA was obtained from cell line pellets by standard phenol-chloroform (1:1) extraction followed by ethanol precipitation [32] or by using DNeasy Tissue Kit (QIAGEN, Valencia, CA). Total RNA was obtained from cell lines using RNeasy Plus Mini Kit (QIAGEN). cDNA was prepared as described previously [14].
###end p 23
###begin title 24
Gene Sequencing
###end title 24
###begin p 25
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu2">[10]</xref>
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu3">[32]</xref>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3</italic>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu2">[10]</xref>
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s006">Table S6</xref>
DNA sequencing and mutational analysis for EGFR (exons 18-21), HER2 (exons 19 and 20), KRAS (codons 12, 13, and 61), BRAF (exons 11 and 15) and PIK3CA (exons 9 and 20) were done as reported by us previously [10], [14], [32]. HER3 (exons 18-21) and HER4 (exons18-23) mutation status were analyzed by PCR amplification of genomic DNA or cDNA and direct sequencing of the PCR products [10]. The mutations in these genes were determined using the PCR primers as listed (Table S6). All PCRs were performed in 25 microL volumes containing 100 ng of DNA using HotStarTaq DNA polymerase (QIAGEN Inc., Valencia, CA). DNA was amplified for 32 to 34 cycles at 95degreesC for 30 seconds, 62degreesC to 68degreesC for 30 seconds, and 72degreesC for 30 seconds followed by 7 minutes extension at 72degreesC. All PCR products were incubated using exonuclease I and shrimp alkaline phosphatase (Amersham Biosciences Co., Piscataway, NJ) and sequenced directly using Applied Biosystems PRISM dye terminator cycle sequencing method (Perkin-Elmer Co., Foster City, CA). All mutations were confirmed by independent sequencing in both directions.
###end p 25
###begin title 26
Copy number evaluation
###end title 26
###begin p 27
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Lyng1">[33]</xref>
Copy number gains can be evaluated by a number of methodologies. For clinical samples, fluorescence in situ hybridization (FISH) is frequently used as it can discriminate between tumor and non-malignant cells. Laboratory studies of tumor cell lines (which are free of non-malignant cells) often utilize quantitative PCR (qPCR). An alternative method is array comparative genomic hybridization (aCGH). Because direct comparisons of these methods have seldom been reported [33], we utilized all three methods.
###end p 27
###begin title 28
Real-time qPCR
###end title 28
###begin p 29
###xml 258 266 258 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s006">Table S6</xref>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 433 437 433 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 688 696 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s006">Table S6</xref>
###xml 1159 1160 1111 1112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1380 1381 1332 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1448 1452 1400 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Bieche1">[34]</xref>
###xml 1522 1523 1474 1475 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1525 1526 1477 1478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 1530 1531 1482 1483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1533 1534 1485 1486 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sub>
###xml 1537 1543 1489 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1599 1603 1551 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
Gene copy numbers were determined using real-time quantitative PCR employing the Chromo4 PCR System (Bio-Rad Laboratories, Hercules, CA). To determine the copy number of a target gene, we used control genes located on the same chromosome as the target gene (Table S6). The resultant ratios were compared to similar ratios from diploid cells (the mean values of the eight HBEC cell lines. TaqMan methodology was used except for PIK3CA[14]. Primers and probes were chosen by TaqMan Primer Expresstrade mark 1.5 (Applied Biosystem, Foster City, CA). Primers were purchased from Invitrogen and probes from Biosearch Technologies (Novato, CA). The sequences of primers and probes are shown in Table S6. Standard curves were constructed with serial dilutions of specific PCR products. Amplification mixes (25 microl) contained the sample DNA (20 ng), 10x TaqMan buffer (2.5 microl), 200 microM dNTP, 1.25 U Hotstar Taqtrade mark DNA polymerase, 200 nM each primer and 100 nM probe. The thermal cycling conditions comprised 5 min at 95degreesC and 40 cycles at 95degreesC for 15 s and 60degreesC for 30 s. All the samples were analyzed in triplicate. The parameter Ct is defined as the fractional cycle number at which the fluorescence generated by cleavage of the probe passes a fixed threshold above baseline. The target gene copy number in unknown samples is quantified by measuring Ct values and by using a standard curve to determine the copy number [34]. Gene copy number was calculated using the following equation: g = (ST/SC)/(NT/NC). PIK3CA copy number was assessed as described by us previously [14].
###end p 29
###begin title 30
Tiling path aCGH
###end title 30
###begin p 31
###xml 43 47 43 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 49 53 49 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Lockwood1">[15]</xref>
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Jong1">[35]</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Coe1">[36]</xref>
aCGH was performed as previously described [14], [15]. Genomic imbalances were identified using aCGH-Smooth [35] as previously described [36].
###end p 31
###begin title 32
FISH assays
###end title 32
###begin p 33
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-VarellaGarcia1">[37]</xref>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Helfrich1">[38]</xref>
Dual-color FISH assays were performed according to a standard protocol [37], [38]. The probe sets, EGFR/CEP7 and PathVysion and the controls CEP7 were obtained from Abbott Molecular (Des Plaines, Illinois), HER3/CEP12 was obtained from QBiogene; BRAF probe was generated from the bacterial artificial clone (BAC) clone used for aCGH. The copy numbers of the target genes (labeled in red fluorophores) and the CEP probes (labeled in Spectrum Green) were verified in at least 100 interphase cells and 20 metaphase spreads. Images were captured and merged using the CytoVision workstation (Applied Imaging, San Jose, CA).
###end p 33
###begin title 34
Sub-cloning
###end title 34
###begin p 35
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 411 415 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Genomic DNA was isolated from mutant EGFR or KRAS NSCLC cell lines and used as a template for PCR amplification of EGFR or KRAS. The primers and the conditions of PCR reactions were as described previously. PCR products were cloned into pCR2.1-TOPO vector using TOPO TA cloning kit (Invitrogen). About 20 clones (range15-25) were selected for sequencing using either M13 forward primer or corresponding EGFR or KRAS primers. The results are expressed as the percentages of mutant alleles present in the total number cloned.
###end p 35
###begin title 36
TKI sensitivity
###end title 36
###begin p 37
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
The MTS colorimetric assay (Promega) was performed as per the manufacturer's instructions. This assay is based on the conversion of MTS into soluble formazan by endogenous dehydrogenase enzymes found in metabolically active cells. Cells were plated at 1x103-4x103 cells/well in tissue culture treated 96-well plates. The following day, TKI (gefitinib or erlotinib) was added to each plate in a dilution series across the plate such that eight different concentrations of the drug were tested. On day 5, 20 microl of MTS was added, followed by a 1 hour incubation at 37degreesC and then the absorbance was read at 490 nm on a plate reader.
###end p 37
###begin p 38
###xml 50 51 50 51 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</underline>
###xml 76 77 76 77 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</underline>
96-well plate data were imported into an in-house Database of In VItro drug Sensitivity Assays (DIVISA by Luc Girard, manuscript in preparation) where IC50s are calculated as well as various statistical analyses. To calculate IC50 values, the data were background-subtracted (columns 1 and 12 typically contained media with no cells or drugs and served as background values), and fitted to the DRC model (R package 'drc' by Christian Ritz and Jens Streibig, ) to generate a sigmoidal curve from which the concentration that inhibits 50% of the cells (IC50) was determined.
###end p 38
###begin title 39
Statistical Analyses
###end title 39
###begin p 40
###xml 223 230 223 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3">Results</xref>
Fisher's two-tailed exact tests were determined using the Prism 4 software (Graph Pad, San Diego, CA). P values<0.05 were considered significant. Other statistical analyses are discussed under appropriate categories in the Results section.
###end p 40
###begin title 41
Results
###end title 41
###begin title 42
Mutations (m) and CNGs (g) in lung cancer cell lines
###end title 42
###begin p 43
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 280 288 280 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s001">Table S1</xref>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 358 366 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s002">Table S2</xref>
###xml 406 410 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
We examined 32 SCLC and three lines from small cell cancers from extrapulmonary sites (extrapulmonary small cell cancers, ExPuSC), for somatic mutations and CNGs of EGFR pathway genes. We found a total of only three mutations in 35 cell lines and all three were PIK3CA mutations (Table S1). CNGs for EGFR pathway genes were infrequently encountered in SCLC (Table S2). Since somatic mutations and CNGs for EGFR pathway genes were rare in SCLC, we limited our further studies to NSCLC.
###end p 43
###begin p 44
For any of the seven genes tested, mutations (39/77, 50.6%), copy number gains (50/77, 64.9%) or either (65/77, 84.4%) were frequent in NSCLC lines. These findings are discussed in greater detail below.
###end p 44
###begin title 45
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Mutations (m) of EGFR pathway genes in NSCLC
###end title 45
###begin p 46
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 90 97 90 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Methods</xref>
###xml 166 172 166 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g001">Fig 1a</xref>
###xml 174 182 174 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s003">Table S3</xref>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 288 292 288 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3</italic>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 410 414 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 558 565 558 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g001">Fig. 1c</xref>
We examined the NSCLC lines, for somatic mutations of EGFR pathway genes as listed in the Methods section. We found a total of 40 mutations in 39 (50.6%) cell lines (Fig 1a, Table S3). These mutations consisted of 19 KRAS (24.7%), 10 EGFR (13%), five BRAF (6.5%), four PIK3CA (5.2%), one HER2 (1.3%), one HER4 (2.2%) and none for HER3. mEGFR, mBRAF and mHER2 were present exclusively in adenocarcinomas while mKRAS were more frequent in adenocarcinoma and large cell histologies. mPIK3CA were the only mutations that did not target adenocarcinoma histology (Fig. 1c).
###end p 46
###begin title 47
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Mutations (m) and Copy number gains (g) of EGFR pathway genes in NSCLC.
###end title 47
###begin p 48
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 885 889 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 894 898 894 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 960 964 960 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 1017 1021 1017 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 1189 1193 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1198 1204 1198 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Fig 1a. shows the frequency of mutations and copy number gains of EGFR pathway genes (EGFR, KRAS, BRAF, PIK3CA, HER2, HER3 and HER4). Forty mutations were identified in 39 cell lines. Mutations and copy number gains were more frequent for EGFR (13%, 40.3%) and KRAS (24.7%, 14.3%) than other gene. CNGs for HER2 (18.2%) were also common. We identified only one HER2 and one HER4 somatic mutation. The numbers above the columns indicate the number of cell lines with mutations (blue columns) or copy number gains (red columns). Fig 1b. The figure depicts the number of genes demonstrating CNGs in mutant and wild type cell lines. Of the 77 cell lines examined, 39 (50.6%) had a mutation in at least one of seven the EGFR pathway genes examined. CNGs were frequent in both mutant and wild type cell lines. Fig 1c. shows frequency of mutations on the basis of NSCLC subtype. Mutations of EGFR and BRAF were exclusively found in adenocarcinoma subtype. The single HER2 mutation was in a adenocarcinoma as compared to the HER4 somatic mutation which was identified in a squamous cell ca. Fig 1d. shows frequency of copy number gains (CNGs) (g>4 by qPCR) on the basis of NSCLC subtype. CNGs for BRAF and PIK3CA were seen predominantly in adenocarcinoma and squamous cell carcinoma respectively. CNGs for the rest of the genes did not favor any subtype.
###end p 48
###begin title 49
Mutations are mutually exclusive
###end title 49
###begin p 50
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
We examined for any association between somatic mutations in individual cell lines. In order to test the hypothesis that EGFR pathway gene mutations are mutually exclusive, we used Monte Carlo simulations to calculate the empirical p-value. The null hypothesis is that mutations will occur independently. We simulated the joint distribution of mutation events among these seven genes using the observed marginal mutation rates and the independent assumption. In each simulation, we noted the number of cell lines with multiple mutations. We repeated the simulations 10,000 times and obtained the empirical distribution of the number of cell lines with multiple mutations; then we compared the observed number of cell lines with multiple mutations with this empirical distribution to calculate the p-value.
###end p 50
###begin p 51
###xml 213 220 213 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t001">Table 1</xref>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 276 282 276 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
For this study, the one-sided p-value is 0.0014; therefore, we rejected the null hypothesis and concluded that gene mutations are mutually exclusive events for these genes in NSCLC cell lines, with one exception (Table 1). Large cell carcinoma line NCI-H460 had both KRAS and PIK3CA mutations.
###end p 51
###begin title 52
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Are mutations of EGFR pathway genes mutually exclusive?
###end title 52
###begin p 53
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t001">Table 1</xref>
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Table 1 shows that mutations of EGFR pathway genes are mutually exclusive in NSCLC (p<0.05). The only exception was a cell line which harbored mutations for both KRAS and PIK3CA mutations.
###end p 53
###begin title 54
Comparison of methods for determining copy number gains
###end title 54
###begin p 55
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Everit1">[39]</xref>
###xml 865 872 865 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t002">Table 2</xref>
###xml 176 181 <span type="species:ncbi:9606">human</span>
aCGH, FISH and qPCR were used to test the gene copy numbers for NSCLC cell lines. There is no clear biological threshold value for defining the abnormal copy numbers for NSCLC human cell lines; we selected the threshold values which could achieve the best positive or negative category agreement among the three tests. Specifically, we computed the Kappa statistics [39] between aCGH and qPCR tests over two dimensional cut-off grids as 2, 2.5, 3, 3.5, 4, 4.5 and 5; and then did the same for FISH and qPCR. The cut-off values that achieved the best agreement among three tests were as follows: 4 for qPCR, 3 for CGH and 4.5 for FISH; and we used these values to define the presence of copy number gains in NSCLC cell lines. Using these cut-off values and all available data, there was highly significant concordance (p<0.001) between the three methods as shown in Table 2.
###end p 55
###begin title 56
Comparison of the three methods used for studying gene copy number.
###end title 56
###begin p 57
Gene copy number was measured using three methods, qPCR, aCGH and FISH. All samples used in this study had qPCR data and subset data for the other two methods. All available data were pooled and used for analysis of concordance and kappa statistics. All three comparisons show high concordance with low p values. Kappa analyses were used to determine the optimal cut-off value for each test. These analyses yielded the following cut-off values for determining copy number gains: qPCR>/=4.0, aCGH>/=3.0 and for FISH>/=4.5. Using these cut-off values, samples were scored as positive or negative for copy number gains for each type of test, and Fishers two sided tests were used for comparisons of the different tests.
###end p 57
###begin title 58
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
EGFR pathway gene CNGs
###end title 58
###begin p 59
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER3</italic>
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 252 258 252 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g001">Fig 1a</xref>
###xml 260 268 260 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s004">Table S4</xref>
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 400 404 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 449 455 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 557 564 557 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g001">Fig. 1c</xref>
As the qPCR data were complete for all lines (while subsets were tested by the other two methods which are more laborious and expensive), we used qPCR data for all further analyses. Copy number gains were frequent (>10%) for EGFR, HER2, HER3 and KRAS (Fig 1a, Table S4). In particular gains for EGFR were more than twice as frequent (40%) than for any other gene. In general, with the exceptions of gBRAF (limited to adenocarcinoma histology), and gPIK3CA (largely limited to squamous cell histology), CNGs did not show any apparent histology subtype bias (Fig. 1c).
###end p 59
###begin title 60
Relationship between Mutations and Copy number gains
###end title 60
###begin p 61
###xml 106 112 106 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g002">Fig. 2</xref>
###xml 183 191 183 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s004">Table S4</xref>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 315 325 315 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g003">Fig 3a, 3b</xref>
Unlike mutations, copy number gains were not mutually exclusive either with other CNGs or with mutations (Fig. 2). We found CNGs for two or more genes in 32.5% (25/77) of cell lines (Table S4). However, we noted a highly significant association between mutations of EGFR or KRAS and CNGs of their respective genes (Fig 3a, 3b).
###end p 61
###begin title 62
Copy number gains are not mutually exclusive with either other copy number gains or with mutations.
###end title 62
###begin p 63
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 238 242 238 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
Fig 2a. shows that copy number gains and mutations are not mutually exclusive. As evident from the figure CNGs for EGFR and KRAS are significantly more frequent in EGFR and KRAS mutant cell lines respectively (p<0.05). There was only one HER2 and HER4 mutant NSCLC cell line and thus they were not included in this figure. Fig 2b. shows that copy number gains are not mutually exclusive and gains of one gene may occur in the presence of gains for other genes.
###end p 63
###begin title 64
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Mutant allele specific imbalance (MASI) for EGFR and KRAS genes.
###end title 64
###begin p 65
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
EGFR and KRAS genes preferentially have copy number gains (CNG) in cell lines harboring the respective mutations (panels a and b). In mutant lines, the mutant allele almost always is in excess compared to the wild type allele (panels c and d), a phenomenon we have termed MASI. In most MASI cases the mutant allele demonstrates CNGs; however MASI may also be present in cell lines having a diploid copy number of the oncogene, (acquired uniparental disomy) either uniform (NCI-H460) or heterogeneous (NCI-H1975).
###end p 65
###begin title 66
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Mutant allele specific imbalance (MASI) for EGFR and KRAS genes
###end title 66
###begin p 67
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 306 312 306 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g003">Fig. 3</xref>
###xml 674 678 674 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Jung1">[40]</xref>
###xml 827 831 827 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 868 872 868 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
As noted above CNGs of EGFR and KRAS were more frequent in cell lines harboring these mutations. Employing the sub-cloning method previously described, we investigated whether the EGFR and KRAS genes preferentially demonstrated mutant allele specific CNGs in cell lines harboring the respective mutations (Fig. 3). The data, for testing whether mutant alleles are amplified in gene mutant cell lines are clustered data with binary outcome. Each cell line is a cluster and the null hypothesis is that the mutation rate is 0.5. Because the number of subclones in each cell line varied, we used the analysis approach for the clustered binary outcome with various cluster sizes [40]. In mutant lines, the mutant allele was almost always in excess compared to the wild type allele, a phenomenon we have termed MASI. The p-value for EGFR mutant cell lines was 0.019 and for KRAS mutant cell line was 0.0003 indicating that the mutant alleles were preferentially dominant in both cases. Most MASI cases were due to increased copy number of the mutant allele. However, in a minority of cases MASI was also noted in cells having diploid or near diploid copy numbers (acquired uniparental disomy). Thus we used the term MASI as opposed to mutant allele specific gains.
###end p 67
###begin title 68
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Characteristics of EGFR Mutant Cell Lines
###end title 68
###begin p 69
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t003">Table 3</xref>
###xml 396 400 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 621 625 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 355 362 <span type="species:ncbi:4097">tobacco</span>
The clinico-pathologic and molecular data for the 10 NSCLC cell lines which harbor EGFR mutations are summarized in Table 3. All contained one of the two major mutations in the kinase domain, either deletions of exon 19 (n = 7) or L858R mutation in exon 21 (n = 3). Mutations were exclusively seen in adenocarcinoma and never smokers or patients with low tobacco exposure (</=10 pack years). One EGFR mutant cell line was developed in Japan and the remaining nine were developed in North America. Of the nine developed in North America, only one was from an individual of Asian ethnicity. In addition, we identified that EGFR mutations were more common in comparatively younger age group (<55 years).
###end p 69
###begin title 70
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Characteristics of EGFR Mutant Cell Lines.
###end title 70
###begin p 71
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t003">Table 3</xref>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 345 349 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 593 597 591 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 279 286 <span type="species:ncbi:4097">tobacco</span>
###xml 660 667 <span type="species:ncbi:9606">patient</span>
###xml 747 754 <span type="species:ncbi:9606">patient</span>
Table 3 shows the clinico-pathologic and molecular data for the 10 NSCLC cell lines, which harbor EGFR mutations. These cell lines are arranged in decreasing order of gefitinib sensitivity. Mutations were exclusively seen in adenocarcinoma and never smokers or patients with low tobacco exposure (</=10 pack years or PY). The primary activating EGFR mutations in all 10 cases were either deletions of exon 19 (n = 7) or L858R mutation in exon 21 (n = 3). Three cell lines also had a second mutation, either T790M resistance associated mutation in exon 20 (n = 2) or homozygous deletion of the PTEN gene. Contradictory data are available for the gender for the patient from whom the PC-9 cell line was originated - the surgeon informed us that the patient was female while the distributing institution states that it was from a male (personal communication from Dr. Harubumi Kato, Tokyo Medical University, Japan). Cell lines considered resistant to gefitinib (IC50>1 microM) are indicated in red. Rank order is the sensitivity of cell lines to gefitinib in descending order with 1 being the most sensitive. Abbreviations: EA - East Asian, W - White, PY - pack years, Del - deletion.
###end p 71
###begin p 72
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Guo1">[41]</xref>
Seven of these cell lines were sensitive to gefitinib. The three resistant lines had a second mutation: either the T790M resistance associated mutation in exon 20 (n = 2) or a homozygous deletion of the PTEN gene and absence of its protein [41] (authors' unpublished observations).
###end p 72
###begin title 73
Effects of mutations and copy number gains on sensitivity to TKIs
###end title 73
###begin p 74
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 367 373 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 430 436 430 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 535 543 535 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s005">Table S5</xref>
To evaluate the effect of mutations and copy number gains on sensitivity to TKIs, we analyzed the IC50 values of 45 NSCLC cell lines. Because TKI clinical sensitivity preferentially targets adenocarcinoma histology, we included 31 adenocarcinomas. The entire subset included all of the EGFR, HER2 and HER4 mutant cell lines and 12 KRAS and 3 BRAF cell lines. Because PIK3CA mutations favored non-adenocarcinoma histology only one PIK3CA mutant cell line was included. Of the entire subset 17 lines were wild type for all genes tested (Table S5).
###end p 74
###begin p 75
###xml 102 107 102 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g004">Fig 4</xref>
###xml 109 117 109 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004576.s007">Table S7</xref>
We found an excellent concordance between the IC50 values between gefitinib and erlotinib (p<0.0001) (Fig 4, Table S7). Because our data set for gefitinib sensitivity was more extensive we elected to utilize the gefitinib data for further analyses.
###end p 75
###begin title 76
Concordance between IC50 values for gefitinib vs erlotinib.
###end title 76
###begin p 77
Forty five cell lines were tested for sensitivity to both drugs and the concordance was excellent (p<0.0001).
###end p 77
###begin p 78
###xml 0 6 0 6 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g005">Fig. 5</xref>
###xml 385 388 381 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Sharma1">[7]</xref>
###xml 621 627 597 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g005">Fig. 5</xref>
###xml 784 790 756 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004576-g005">Fig. 5</xref>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
Fig. 5 illustrates the sensitivity patterns of the tested cell lines. The in vitro concentration of 1 microM used in tissue culture correlates to the plasma concentration of gefitinib in patients treated with the standard dose of gefitinib i.e. 250 mg a day. This threshold has been used by researchers in the past to distinguish sensitive from insensitive and/or resistant cell lines [7]. On the basis of the above-mentioned threshold and the shape of the curve, we divided our cell lines into 3 categories: sensitive (</=1 microM), intermediate (>1 microM but </=10 microM) and resistant (>10 microM) as seen in figure Fig. 5. The IC50 values follow a line that demonstrated a slope change point at approximately 10 microM, and thus demonstrated an apparently bimodal distribution (Fig. 5). As cell lines with values below 1 microM were regarded as sensitive, we arbitrarily categorized values between 1 and 10 microM as being intermediate in sensitivity.
###end p 78
###begin title 79
Rank Order of NSCLC Cell Line depending on the Iressa IC50.
###end title 79
###begin p 80
###xml 304 308 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 337 341 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 362 366 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 385 389 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 506 510 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 524 528 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Fig 5. shows a log curve of the gefitinib IC50 values for 45 NSCLC cell lines. They are classified into three categories on the basis of gefitinib IC50: Sensitive (IC50<1 microM), Intermediate (IC50>1 but <10 microM) and Resistant (IC50>10 microM). Of the nine sensitive cell lines, seven of them harbor EGFR mutations, one has CNGs for EGFR and one has CNG for HER2. Of the remaining EGFR mutant cell lines, two had T790M mutation (one intermediate and one resistant) and one had a homozygous deletion of PTEN (resistant). KRAS mutant and wild type cell lines were all resistant to gefitinib.
###end p 80
###begin p 81
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 550 554 550 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 562 566 562 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER4</italic>
###xml 571 577 571 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
There were nine cell lines in the sensitive group and they included seven of the ten mEGFR lines, one gEGFR cell line and one gHER2 cell line. The intermediate category consisted of only two cell lines; a mEGFR cell line having a secondary T790M mutation and a gHER2 cell line. The resistant cell line category was the largest and included two mEGFR cell lines, one having the secondary T790M mutation and the other having homozygous deletion of PTEN gene. The remaining resistant lines included all of the wild type lines and all lines having KRAS, BRAF, HER2, HER4 and PIK3CA mutations.
###end p 81
###begin p 82
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 374 378 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 711 718 711 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t005">Table 5</xref>
Using univariate tests, we analyzed the association between gefitinib sensitivity and mutational status or CNGs of the various EGFR pathway genes and found a significant correlation between gefitinib sensitivity with EGFR mutation (p = 0.002) and EGFR copy number gains (p = 0.001). We tested the hypothesis that KRAS mutations confer intrinsic resistance to TKIs. Because mEGFR was associated with sensitivity to TKIs we excluded these lines from our analyses. We compared the rank order of IC50s of mKRAS cell lines with a) all other cell lines and b) cell lines wild type for all other tested genes. Our univariate analyses demonstrated that indeed KRAS mutations conferred in vitro resistance to gefitinib (Table 5). None of the other gene mutations or copy number gains showed any significant correlation with gefitinib sensitivity.
###end p 82
###begin p 83
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Netter1">[42]</xref>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 172 179 172 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t004">Table 4</xref>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 471 475 471 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 480 484 480 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 669 673 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 881 885 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 898 902 898 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 908 912 908 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 1046 1050 1046 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1055 1059 1055 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 1100 1104 1100 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1200 1204 1200 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 1271 1278 1271 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004576-t004">Table 4</xref>
We then used a multivariate linear regression model [42] to explore the association between gefitinib sensitivity and EGFR mutation, EGFR copy number and HER2 copy number (Table 4). The response variable was log IC50 values of gefitinib (as a continuous variable), the predictors are EGFR mutation status (mutation or wild type EGFR), EGFR copy number (measured by qPCR) and HER2 copy number (measured by qPCR) as continuous variables. After adjusting for the effects of EGFR and HER2 copy numbers, the EGFR mutation status was significantly associated with the gefitinib sensitivity (p<0.001). Similarly after adjusting for the effects of the other two variables, the EGFR copy number (p value = 0.002) and HER2 copy number (p = 0.021) were independently and significantly associated with the gefitinib sensitivity. To summarize the multivariate analysis, all 3 parameters, i.e. mEGFR mutations, gEGFR and gHER2, showed a correlation with TKI sensitivity in decreasing order of importance. We also repeated the analysis using the copy number of EGFR and HER2 as binary variables. In these analyses, EGFR copy number remained significantly associated with gefitinib sensitivity (p value<0.001) while HER2 copy number was no longer significantly associated (p value>0.05; Table 4).
###end p 83
###begin title 84
Results of Multivariate Regression Analyses.
###end title 84
###begin p 85
###xml 209 211 209 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
From the multivariate regression analyses three variables were found to be independently associated with gefitinib sensitivity and are listed in descending order of importance. The response variable is the log10(IC50) values of gefitinib.
###end p 85
###begin p 86
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
After adjusting for the effects of EGFR and HER2 copy numbers, the EGFR mutation status is significantly associated with gefitinib sensitivity as indicated in the "Estimate" column of the Table. The association coefficient is -1.5, which means after adjusting for EGFR and HER2 copy number effects, the IC50 for EGFR wild type cell lines is 32 fold higher that that of EGFR mutation cell lines.
###end p 86
###begin p 87
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
After adjusting for the effects of EGFR mutation and HER2 copy numbers, the EGFR copy number is significantly associated with gefitinib sensitivity. The association coefficient is -0.07, which means after adjusting for EGFR mutation and HER2 copy number effects, the IC50 will decrease 0.85 fold when EGFR relative copy number increases 1 unit.
###end p 87
###begin p 88
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
After adjusting for the effects of EGFR mutation and EGFR copy numbers, the HER2 copy number is significantly associated with gefitinib sensitivity. The association coefficient is -0.01, which means after adjusting for EGFR mutation and EGFR copy number effects, the IC50 will decrease 0.98 fold when HER2 relative copy number increases 1 unit.
###end p 88
###begin p 89
to the base 10.
###end p 89
###begin title 90
Do KRAS mutations confer resistance to TKIs?
###end title 90
###begin p 91
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Wilcoxon signed rank one-sided test was used to test the hypothesis that mKRAS confers intrinsic resistance to TKIs. We compared the median rank order of gefitinib IC50 values of mKRAS cell lines to all other lines excluding EGFR mutant lines (Comparison 1) and cell lines wild type for all the other genes tested (Comparison 2). For both analyses EGFR mutant cell lines were excluded as they were associated with sensitivity to TKIs.
###end p 91
###begin title 92
Discussion
###end title 92
###begin p 93
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
In order to clarify some of the conflicting data from clinical studies, we performed an in vitro study of deregulation of the EGFR signaling pathway in a large panel of lung cancer cell lines and correlated the results with TKI sensitivity. In contrast to SCLC, mutations or CNGs of the studied genes were frequent in NSCLC - 84.4% of NSCLC cell lines had a mutation, one or more CNGs or both. Thus the EGFR pathway is deregulated at high frequency in NSCLC.
###end p 93
###begin p 94
###xml 180 184 180 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 355 358 355 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu1">[3]</xref>
###xml 360 363 360 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Eberhard1">[8]</xref>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu2">[10]</xref>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Naoki1">[12]</xref>
###xml 377 381 377 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Marks1">[43]</xref>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 404 408 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 523 526 523 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER</italic>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 577 583 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 739 745 739 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 906 910 906 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 915 921 915 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 979 983 979 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 985 989 985 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 991 1004 991 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF and HER2</italic>
###xml 1110 1114 1110 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1201 1205 1201 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Shigematsu2">[10]</xref>
###xml 1207 1211 1207 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 1247 1253 1247 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1324 1328 1324 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
###xml 1358 1364 1358 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1369 1373 1369 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1477 1481 1477 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yamamoto1">[14]</xref>
Somatic mutations or CNGs of the studied genes were rare in SCLC and further studies were limited to NSCLC. About half of the NSCLC lines had a mutation in one of the genes of the EGFR pathway. The relative distribution of the mutations of EGFR pathway genes in established NSCLC cell lines were very similar to those reported from large clinical studies [3], [8], [10], [12], [14], [43]. EGFR (13%) and KRAS (24.7%) mutations were more frequently observed than other gene mutations. We found a single mutation of HER2 and HER4 and no mutations of EGFR3. Mutations of BRAF and PIK3CA were intermediate in frequency. In general mutations were more common in adenocarcinoma subtype and relatively rare in squamous cell carcinomas except for PIK3CA which was more common in squamous cell carcinomas, as also occurs in tumors [14]. Mutations were mutually exclusive except for a single cell line that had both KRAS and PIK3CA mutations. We have previously reported that mutations of EGFR, KRAS, BRAF and HER2 were mutually exclusive in 691 resected NSCLC tumors indicating that a single activating mutation in the EGFR-RAS-RAF signaling pathway may be sufficient for the pathogenesis of many lung cancers [10], [14]. However, the mutational status of PIK3CA was not mutually exclusive, which is similar to another recent report [14]. We have postulated that the PIK3CA and EGFR signaling pathways closely interact but that PI3K signaling represents a partially independent pathway [14].
###end p 94
###begin p 95
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1666 1670 1654 1658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Lyng1">[33]</xref>
###xml 1800 1804 1788 1792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Rosenberg1">[44]</xref>
###xml 1990 1994 1978 1982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Lyng1">[33]</xref>
Copy number gains are believed to be an important mechanism for activation of the EGFR pathway genes and the downstream signaling network. CNGs have been difficult to interpret due to the differences stemming from the use of different methods. Our comparison of the three methods yielded excellent concordance for binary values after we used kappa statistics to determine the optimal cut off values for increased copy numbers. However, the three methods we compared have their individual advantages and disadvantages. CNGs result from gene over-representation due to chromosomal polysomy or focal amplification. FISH, a widely used technique to assess gene copy number takes can identify gains due to both mechanisms. On the other hand, not only is it expensive and time consuming but it analyzes only a small subset of cells (approximately100 cells) to assess the copy number, and tandem segmental duplications may not always be detected. Thus intratumoral heterogeneity is difficult to assess. Both aCGH and qPCR analyze DNA from many thousands of cells, but because they compare values for the test gene against an internal standard (a reference locus), they can detect focal amplifications more readily than polysomy. In the case of qPCR, if the amplicon encompasses the reference locus, then amplification may be underestimated. In the case of aCGH, the copy number deduced from the signal ratio can appear lower than those obtained by the other two techniques, for aCGH measures relative and not absolute copy number. It does not take into account changes in ploidy and therefore will dampen ratio shifts for copy number gains in samples with a high DNA index [33]. Thus, the absolute copy number for a given chromosome region is best determined by using a combination of complementary methods [44]. Despite the shortcomings of each method, we found a high concordance among the three techniques when using binary values (normal/increased), similar to findings in a recent comparison [33]. We had most extensive data for gene copy number generated via qPCR and used it for all our further analysis.
###end p 95
###begin p 96
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 124 128 124 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 241 247 241 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Sixty seven percent of the NSCLC lines had CNGs for one or more EGFR pathway genes. CNGs for EGFR (40.3%), HER2 (18.2%) and KRAS (14.3%) were more frequent than the other genes. BRAF CNGs (13%) were more common in adenocarcinoma subtype and PIK3CA CNGs (36.4%) were more frequent in squamous cell carcinoma as compared to the other subtypes. Other genes did not show subtype bias. Unlike mutations, CNGs were not mutually exclusive either with other CNGs or with mutations.
###end p 96
###begin p 97
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Gondek1">[45]</xref>
###xml 557 561 557 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Tyybakinoja1">[46]</xref>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 968 972 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Zhang1">[47]</xref>
###xml 1060 1064 1060 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1069 1073 1069 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1367 1371 1367 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Gazdar2">[48]</xref>
###xml 1373 1377 1373 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Nomura1">[49]</xref>
###xml 1379 1383 1379 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Soh1">[50]</xref>
###xml 1385 1389 1385 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Yatabe1">[51]</xref>
###xml 1448 1452 1448 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Gazdar2">[48]</xref>
###xml 1454 1458 1454 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Nomura1">[49]</xref>
###xml 1460 1464 1460 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Soh1">[50]</xref>
###xml 1466 1470 1466 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Zhang2">[52]</xref>
###xml 1472 1476 1472 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Tang1">[53]</xref>
However, CNGs were not completely random. We identified that EGFR and KRAS CNGs were significantly more frequent in EGFR and KRAS mutant cell lines respectively. Using subcloning, we determined that in almost all mutant lines with CNGs, the mutant allele was in great excess in comparison to the wild type allele. In some lines with diploid amounts of the mutant gene, the wild type allele was absent or in minute amounts. This finding for oncogenes (as compared to tumor suppressor genes) has been described, particularly in hematologic malignancies [45], [46], and represents a form of acquired uniparental disomy. Taken together, we term this phenomenon as mutant allele specific imbalance (MASI). Thus MASI may result from specific amplification of the mutant allele, or by loss of the wild type gene, or by a combination of these events. Of interest, wild type KRAS may function as an inhibitor of tumorigenesis and thus represent a form of tumor suppressor gene [47]. These results suggest that the combination of two methods of activating the oncogenes EGFR and KRAS (i.e. mutation and MASI) may confer a greater growth or survival advantage to the malignant cell than a single method. These findings also indicate that mutations must precede CNGs in cells harboring both changes. Other evidence for the combination of mutations and CNGs in tumor cells exists [48], [49], [50], [51], and for the concept that mutations are the initial event [48], [49], [50], [52], [53].
###end p 97
###begin p 98
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
EGFR mutations were exclusively found in adenocarcinoma histology and in never smokers or individuals with low smoke exposure (<15 PYR). In addition EGFR mutations were more common in a comparatively younger age group (<55 years). EGFR mutations did not demonstrate gender bias. Most mutant lines were derived from Caucasians, which is not surprising considering that 90% were established in the USA. In rank order of sensitivity to gefitinib, nine of the EGFR mutant lines were represented in the 12 most sensitive lines, in keeping with the previously discussed importance of mutations in sensitivity to TKIs.
###end p 98
###begin p 99
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 579 583 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Mellinghoff1">[54]</xref>
We found an excellent concordance between the IC50 values between gefitinib and erlotinib. Depending on the previously determined in vitro threshold for gefitinib and the bimodal curve we classified our NSCLC cell lines into 3 categories: sensitive, intermediate and resistant. We had nine sensitive cell lines which included seven of the 10 EGFR mutant cell lines, one cell line with EGFR CNG and one with HER2 CNG. Of the remaining 3 EGFR mutant cell lines, two had the resistance associated secondary T790M mutation. The third resistant EGFR mutant line had a deletion of the PTEN gene, a finding associated with TKI resistance in other systems [54].
###end p 99
###begin p 100
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004576-Pao2">[28]</xref>
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Pao et al demonstrated that mutations in KRAS are associated with a lack of sensitivity to TKIs [28]. We tested the hypothesis that KRAS mutations confer intrinsic resistance to TKIs and our univariate analyses demonstrated that indeed KRAS mutations conferred in vitro resistance to gefitinib. Thus KRAS mutations are associated with both clinical and in vitro resistance to gefitinib.
###end p 100
###begin p 101
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
None of the other gene mutations or copy number gains showed any significant correlation with gefitinib sensitivity. In the clinical setting, approximately 10-20% of NSCLC patients who do not harbor identifiable EGFR mutations respond partially to gefitinib. Evidently EGFR mutations are one of the most important but not the sole determinant of TKI response.
###end p 101
###begin p 102
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER2</italic>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 827 831 827 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 394 401 <span type="species:ncbi:9606">patient</span>
###xml 631 639 <span type="species:ncbi:9606">patients</span>
We evaluated the effect of EGFR mutation, EGFR CNGs and HER2 CNGs on TKI sensitivity using a multivariate regression analysis. To summarize the multivariate analysis, all 3 parameters, i.e. EGFR mutations, EGFR CNG and HER2 CNG, showed a correlation with the TKI sensitivity (used as a continuous variable) in decreasing order of importance. Thus three previously identified factors related to patient response to TKIs are major factors in the in vitro response. However, the most important independent factor is the presence of activating EGFR mutations. Our findings may assist in the prediction of response and the selection of patients for targeted therapies. Another important finding was the frequent presence of selective imbalance of the mutant form (MASI) of oncogenes in tumor cells that harbor mutations of EGFR and KRAS. While MASI may confer a selective advantage to the tumor cell, its effect on clinical course or response to therapy remains to be determined.
###end p 102
###begin title 103
Supporting Information
###end title 103
###begin p 104
(0.01 MB PDF)
###end p 104
###begin p 105
Click here for additional data file.
###end p 105
###begin p 106
(0.01 MB PDF)
###end p 106
###begin p 107
Click here for additional data file.
###end p 107
###begin p 108
(0.01 MB PDF)
###end p 108
###begin p 109
Click here for additional data file.
###end p 109
###begin p 110
(0.02 MB PDF)
###end p 110
###begin p 111
Click here for additional data file.
###end p 111
###begin p 112
(0.02 MB PDF)
###end p 112
###begin p 113
Click here for additional data file.
###end p 113
###begin p 114
(0.01 MB PDF)
###end p 114
###begin p 115
Click here for additional data file.
###end p 115
###begin p 116
(0.02 MB PDF)
###end p 116
###begin p 117
Click here for additional data file.
###end p 117
###begin title 118
References
###end title 118
###begin article-title 119
Lung cancer in never smokers-a different disease.
###end article-title 119
###begin article-title 120
Cancer statistics, 2008.
###end article-title 120
###begin article-title 121
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.
###end article-title 121
###begin article-title 122
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
###end article-title 122
###begin article-title 123
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
###end article-title 123
###begin article-title 124
EGFR and cancer prognosis.
###end article-title 124
###begin article-title 125
Epidermal growth factor receptor mutations in lung cancer.
###end article-title 125
###begin article-title 126
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
###end article-title 126
###begin article-title 127
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
###end article-title 127
###begin article-title 128
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
###end article-title 128
###begin article-title 129
###xml 48 53 <span type="species:ncbi:9606">human</span>
Somatic mutations of the ERBB4 kinase domain in human cancers.
###end article-title 129
###begin article-title 130
###xml 39 44 <span type="species:ncbi:9606">human</span>
Missense mutations of the BRAF gene in human lung adenocarcinoma.
###end article-title 130
###begin article-title 131
###xml 50 55 <span type="species:ncbi:9606">human</span>
High frequency of mutations of the PIK3CA gene in human cancers.
###end article-title 131
###begin article-title 132
PIK3CA mutations and gene copy number in lung cancers.
###end article-title 132
###begin article-title 133
Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines.
###end article-title 133
###begin article-title 134
Regulation of the Ras signalling pathway by protein-tyrosine kinases.
###end article-title 134
###begin article-title 135
Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.
###end article-title 135
###begin article-title 136
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
###end article-title 136
###begin article-title 137
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
###end article-title 137
###begin article-title 138
Erlotinib in previously treated non-small-cell lung cancer.
###end article-title 138
###begin article-title 139
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
###end article-title 139
###begin article-title 140
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
###end article-title 140
###begin article-title 141
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
###end article-title 141
###begin article-title 142
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
###end article-title 142
###begin article-title 143
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer.
###end article-title 143
###begin article-title 144
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
###end article-title 144
###begin article-title 145
###xml 86 94 <span type="species:ncbi:9606">patients</span>
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
###end article-title 145
###begin article-title 146
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
###end article-title 146
###begin article-title 147
Extrapulmonary small cell carcinoma.
###end article-title 147
###begin article-title 148
NCI-Navy Medical Oncology Branch cell line data base.
###end article-title 148
###begin article-title 149
###xml 19 24 <span type="species:ncbi:9606">human</span>
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
###end article-title 149
###begin article-title 150
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
###end article-title 150
###begin article-title 151
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data.
###end article-title 151
###begin article-title 152
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.
###end article-title 152
###begin article-title 153
Breakpoint identification and smoothing of array comparative genomic hybridization data.
###end article-title 153
###begin article-title 154
Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer.
###end article-title 154
###begin article-title 155
Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy.
###end article-title 155
###begin article-title 156
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
###end article-title 156
###begin article-title 157
Sample size calculations for clustered binary data.
###end article-title 157
###begin article-title 158
Signaling networks assembled by oncogenic EGFR and c-Met.
###end article-title 158
###begin article-title 159
Mutational analysis of EGFR and related signaling pathway genes in lung Adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.
###end article-title 159
###begin article-title 160
Comparative genomic hybridization in hypotriploid/hyperdiploid tumors.
###end article-title 160
###begin article-title 161
SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD.
###end article-title 161
###begin article-title 162
Single nucleotide polymorphism microarray analysis of karyotypically normal acute myeloid leukemia reveals frequent copy number neutral loss of heterozygosity.
###end article-title 162
###begin article-title 163
###xml 50 54 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Wildtype Kras2 can inhibit lung carcinogenesis in mice.
###end article-title 163
###begin article-title 164
Deregulated EGFR Signaling during Lung cancer Progression: Mutations, Amplicons and Autocrine loops.
###end article-title 164
###begin article-title 165
Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers.
###end article-title 165
###begin article-title 166
Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.
###end article-title 166
###begin article-title 167
Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.
###end article-title 167
###begin article-title 168
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.
###end article-title 168
###begin article-title 169
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.
###end article-title 169
###begin article-title 170
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors.
###end article-title 170
###begin p 171
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Dr. Gazdar is a paid consultant/lecturer for AstraZeneca PLC. Dr. Garcia recieves Research Funding >10,000 from AstraZeneca, Genentech and OSI; Honorarium <10,000 from Roche. Dr. Minna receives research support from AstraZeneca PLC.
###end p 171
###begin p 172
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Funding was recieved from the Specialized Program of Research Excellence in Lung Cancer (P50CA70907) and Early Detection Research Network, National Cancer Institute, Bethesda, Maryland (U01CA084971). Funds from both grants were utilized for salary support and for performance of assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 172

